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A B S T R A C T
Introduction. Intracavernous alprostadil injection (IAI) is a widely used treatment for sexual rehabilitation (SR) after
radical prostatectomy (RP). It is unknown whether the continuation of IAI beyond 1 year continues to improve
erectile function.
Aims. To assess evolution of sexual function in patients using IAI who are nonresponsive to phosphodiesterase type
5 inhibitors (PDE5i) between 12 (M12) and 24 (M24) months after RP.
Methods. We retrospectively studied 75 men with a nerve-sparing laparoscopic RP, who had normal preoperative
erectile function, and who regularly used IAI for SR for at least 24 months. At M12, no patients had responded to
PDE5i.
Main OutcomeMeasures. At 12 and 24 months, sexual function was assessed with the UCLA Prostate Cancer Index
(UCLA-PCI), International Index of Erectile Function (IIEF)-15, and erection hardness score (EHS) with and
without IAI. We also assessed the satisfaction rate with IAI, injection-related penile pain, and satisfaction of
treatment. Statistical analysis was performed by using t-tests for paired data and Spearman’s rho correlation
coefﬁcients to assess the relationships between scores at M12 and M24.
Results. Improvement of nocturnal erection was noted (UCLA-PCI, question 25); however, no signiﬁcant difference
was found for IIEF-erectile function with (19.60 ± 9.80 vs. 18.07 ± 10.44) and without IAI (4.63 ± 2.93 vs.
4.92 ± 4.15), UCLA-PCI-sexual bother (37.14 ± 21.45 vs. 37.54 ± 19.67), nor the EHS score with (2.97 ± 1.30 vs.
2.57 ± 1.30) and without IAI (0.67 ± 1.11 vs. 0.76 ± 0.10). The rate of satisfaction with treatment decreased over time
(66.6% vs. 46.7%, P = 0.013). Improved response to IAI at M12 was not correlated to improvement in spontaneous
erections at M24.
Conclusion. The response to IAI remained stable after 2 years of treatment, and no signiﬁcant improvement of
spontaneous erections during intercourse attempts was found between M12 and M24. Patients should be informed
of the limited effect of IAI on natural erections after 1 year. Yiou R, Bütow Z, Parisot J, Binhas M, Lingombet
O, Augustin D, de la Taille A, and Audureau E. Is it worth continuing sexual rehabilitation after radical
prostatectomy with intracavernous injection of alprostadil for more than 1 year? Sex Med 2015;3:42–48.
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Introduction
Radical prostatectomy (RP) remains the stan-dard treatment for organ-conﬁned prostate
cancer but continues to cause erectile dysfunction
related primarily to cavernous nerve injury [1].
Despite the use of nerve-sparing techniques, cav-
ernous nerve dissection induces neuropraxia with a
decrease in nitric oxide production. The resulting
absence of erections during the postoperative
period may cause cavernous tissue ﬁbrosis and
veno-occlusive dysfunction, ultimately leading to
permanent erectile dysfunction [2]. To prevent this
sequence of events, early treatment with either
oral erectogenic drugs such as phosphodiesterase 5
inhibitors (PDE5i) [3–5] or intracavernous injec-
tion of vasoactive substances [6–8] is now consid-
ered in patients who wish to recover sexual activity
after RP. The objective of this treatment is to
resume satisfactory intercourse and prevent cav-
ernous tissue damage by improvement in local
oxygen supply [9]. The regular use of erectogenic
drugs is believed to improve spontaneous erections
and is therefore widely advocated for sexual reha-
bilitation (SR) after RP [2,9–12].
In our department, SR after RP relies chieﬂy on
the use of intracavernous alprostadil injections
(IAIs). IAI remains one of the most widely pre-
scribed treatments for post-RP erectile dysfunc-
tion (pRPED) in France [13], predominately
because the costs of this treatment following RP
surgery are reimbursed by public health insurance.
Several studies have demonstrated that erectile
function improves with the early and regular use of
IAI alone [6,14–16] or combined with other
vasoactive substances [3–17]. However, it is not
known how long this treatment should be contin-
ued before the maximal effect is reached. More-
over, IAI often causes penile pain [18], which leads
to a high treatment discontinuation rate (35% in
our experience at 1 year) and hinders the SR
process [16–19]. We have previously shown in a
population of patients with pRPED, and treatment
with or without IAI, that erectile function
improves between the 6th and 12th month after
starting IAI. However, the overall erectile function
remained low after 1 year, and signiﬁcant pain on
erection (>4/10) was still reported by some
patients. Consequently, after 1 year of treatment
with IAI, some patients still have insufﬁcient erec-
tions even when using PDE5i and may express
lassitude toward IAI and/or subsequently report
impaired quality of life due to the constraints of
the treatment. In such situations, it is unknown
whether the SR process should be continued with
further IAI treatment in order to increase the
chances of developing a natural erectile function
or if another therapeutic strategy should be con-
sidered. Other injectable erectogenic preparations
such as Tri-Mix [7] and alprostadil combined with
lidocaine [20] may cause less pain than alprostadil
alone and therefore may be more efﬁcient.
However, in France, one of the Tri-Mix compo-
nents, phentolamine, is not available, and another,
papaverine, is not licensed for intracavernous use.
At present, Tri-Mix is not among the treatments
recommended by the French Urological Associa-
tion (AFU) for erectile dysfunction after RP [21].
As a consequence, IAI and PDE5i represent the
main therapeutic options for SR in France.
Aims
In this study, we investigated whether patients
using IAI for pRPED, who were unresponsive to
PDE5i at 1 year following RP, would continue to
improve their sexual function, whether IAI-
induced or spontaneous erections, when the IAI
treatment was continued for a further year.
Methods
Charts of patients undergoing bilateral nerve-
sparing laparoscopic RP between July 2007 and
July 2010 for localized prostate cancer and who
were enrolled in a SR program consisting of IAI
for at least 2 years were reviewed retrospectively.
All RP procedures were performed by one of three
experienced surgeons in our department.
The SR program consisted of alprostadil
injections (Edex®, Schwarz Pharma, Boulogne
Billancourt, France) self-administered intra-
cavernously commencing 1month after RP surgery
under the supervision of a physician and a nurse. An
information letter explaining the concept of SRwas
given to all patients. Patients were advised to
perform the injection at home twice a week. They
received follow-up at the uro-oncology department
once a week until the injections could be performed
competently. Patients were then reviewed every 6
months.We advised patients to attempt intercourse
as often as possible as part of the SRprocess. PDE5i
(Viagra® 100 mg, Pﬁzer, New York, NY, USA)
treatment was systematically offered after 1 year of
IAI use or before if spontaneous erections were
reported. PDE5i was considered a failure when
patients achieved an erection hardness score (EHS)
of less than two, and therefore were unable to
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achieve penetration, for a minimum of eight trials
with PDE5i. Patients who failed to response to
PDE5i treatment were encouraged to continue the
SR process with IAI.
Included in this study were patients with
an International Index of Erectile Function
(IIEF)-erectile function (EF) score of over 24
preoperatively, patients without presurgery treat-
ment of erectile dysfunction, patients reporting an
EHS of ≤2 when using PDE5i (Viagra® 100) at the
1 year follow-up, and patients continuing the use of
IAI for a minimum of 24 months following RP.
Patients excludedwere thosewho received adjuvant
cancer treatment following RP.
Main Outcome Measures
Patients were invited to complete the IIEF-15
questionnaire that included scores for EF, orgas-
mic function, sexual drive (SD), intercourse satis-
faction (IS), overall satisfaction, the EHS, and the
Global Assessment Questionnaire (GAQ). The
GAQ included the following questions: Q1: “Has
the treatment you have been taking improved your
erectile function?” and Q2: “If yes, has the treat-
ment improved your ability to engage in sexual
activity?” These were completed at 12 and 24
months after RP with reference to experiences of
intercourse when using IAI or any other treat-
ment. The patients were also invited to complete
the EHS and to answer questions 1–5, and 15 on
the EF domain of the IIEF, when not using any
treatment. The satisfaction rate when using IAI
was also identiﬁed by using the following question
[22]: “On the whole, are you satisﬁed with IAI? 1)
Very satisﬁed, 2) Moderately satisﬁed, 3) Neither
satisﬁed nor dissatisﬁed, 4) Moderately dissatis-
ﬁed, 4) Very dissatisﬁed.”
The UCLA Prostate Cancer Index (UCLA-
PCI) questionnaire [23] was used to measure
sexual bother (score min–max: 0–100, the value
of 100 corresponding to the poorest value) and
the return of nocturnal erection (question 25):
“How often have you awakened in the morning
or night with an erection?: 1) never, 2) seldom, 3)
not often (less than half the time), 4) often (more
than half the time), 5) very often (more than 75%
of the time).”
Pain experienced by patients during erections
was assessed separately using a numeric rating
scale ranging from 0 (no pain) to 10 (worst pain
imaginable). We also recorded the number of
injections administered per week, the dose injected
and any other erectogenic treatments used at the
M24 review, as well as any complications associ-
ated with the use of IAI. Finally, the patients were
asked at M24 if they considered that they had
recovered their preoperative erectile function. All
questionnaires were handed to the patients and
once completed were reviewed by the authors with
each patient.
The main comorbidities at the time of RP and
tumor status were also recorded.
This study formed part of a larger program
based at the department of Urology to evaluate
functional urological disorders occurring after RP.
This program was approved by the institutional
review board of the Henri Mondor Hospital.
Statistical Analysis
Descriptive results are presented as the mean
(±standard deviation). The paired t-test was
used for the comparison of continuous variables
between paired groups (changes in scores between
12 and 24 months post-RP). A χ2 test was used to
compare the rates of nocturnal erection (UCLA-
PCI) and satisfaction with treatment by IAI at M12
and M24. Spearman’s rho correlation coefﬁcients
were calculated to identify the potential factors
measured at M12 that may predict erectile func-
tion scores at M24 and their changes between M12
and M24. A two-tailed P value <0.05 was consid-
ered signiﬁcant. All statistical analyses were per-
formed by using Stata v12.1 (StataCorp. 2011,
Stata Statistical Software: Release 12, StataCorp
LP, College Station, TX, USA).
Results
Seventy-ﬁve patients met the inclusion criteria.
Mean age ± SD was 59.4 ± 8.2. Characteristics of
the population are presented in Table 1. Table 2
lists the mean scores at M12 and M24. No signiﬁ-
Table 1 Comorbidities of the population at the time of
radical prostatectomy and tumor status
N (%)
Comorbidities
Diabetes (type 2) 6 (8)
Dyslipidemia 16 (21.3)
BMI, mean ± SD (kg/m2) 25.6 ± 2.6
Tobacco smoking 4 (5.3)
Hypertension 25 (33.3)




Gleason VI 16 (21.3)
Gleason VII 51 (68)
Gleason VIII 8 (10.7)
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cant difference was found between the 12 and 24
months scores with the exception that the satisfac-
tion rate of treatment was lower and reports of
nocturnal erection increased at 24 months
postsurgery. The variation of the mean IIEF-EF
scores was +0.15 ± 7.62 with treatment and
+0.59 ± 3.36 without treatment and showed that
the overall the response to IAI and achievement of
spontaneous erections remained stable. The
IIEF-EF score when no treatment was taken
decreased in 23 patients (30.6%) remained
unchanged in 19 patients (25.3%) and improved in
33 patients (44%) (min +1, max +10) at M24 in
comparison to M12. No case of normalization of
IIEF-EF scores without treatment (>24) was noted,
and no patient considered that they had recovered
their preoperative function.
Overall, 65 patients (86.8%) at M12 and 57
(76%) patients at M24 considered that the treat-
ment improved their erection (GAQ-Q1), and 53
patients (70.7%) at M12 and 46 patients (61.3%)
at M24 considered that IAI improved their ability
to engage in sexual activity (GAQ-Q2).
At M24, 28 patients (37.3%) were using
PDE5i (sildenaﬁl, tadalaﬁl or vardenaﬁl), and two
patients were using a vacuum in association with
IAI.
Table 3 shows the most relevant correlation
coefﬁcients between the sexual scores of patients
at M12 and M24. Signiﬁcant correlations were
found between the response to treatment at M12
(IIEF-EF and EHS with treatment and IIEF-IS)
and in the response to treatment at M24.
However, none of the sexual scores with IAI
users at M12 correlated with IIEF-EF or EHS
scores when not using treatment at M24, sug-
gesting that there was no association between the
response to IAI treatment at M12 and the recov-
ery of spontaneous erections at M24. At M12,
only a high sexual drive score was signiﬁcantly
associated with the recovery of spontaneous erec-
tion and improvement in IIEF-EF scores at M24
when the patient was not taking any treatment,
indicating that patients with a higher libido
achieved a better recovery of spontaneous erectile
function at M24.
Table 2 Mean erectile function, satisfaction, and penile pain scores at 12 (M12) and 24 months (M24) after bilateral
nerve-sparing radical prostatectomy
N = 75 M12 M24 P value
Number of IAI/week 1.88 ± 0.86 1.61 ± 0.69 0.15
Dose injected (μg) 8.97 ± 5.20 10.18 ± 6.13 0.072
Pain at erection (0–10) 2.92 ± 2.70 2.52 ± 2.35 0.66
IIEF-EF with treatment 19.60 ± 9.80 18.07 ± 10.44 0.92
IIEF-EF without treatment 4.63 ± 2.93 4.92 ± 4.15 0.28
IIEF-OF with treatment by IAI 5.18 ± 3.42 5.58 ± 3.42 0.27
IIEF-SD 6.05 ± 2.32 5.93 ± 2.06 0.74
IIEF-IS 7.18 ± 4.11 6.51 ± 4.23 0.69
IIEF-OS 5.48 ± 2.70 5.62 ± 2.56 0.34
EHS with treatment by IAI 2.97 ± 1.30 2.57 ± 1.30 0.47
EHS without treatment by IAI 0.67 ± 1.11 0.76 ± 0.10 0.14
Satisfaction with treatment by IAI, n (%) 0.013
Satisfied
Very satisfied 16 (21.3%) 9 (12%)
Moderately satisfied 34 (45.3%) 26 (34.7%)
Not satisfied
Neither satisfied nor dissatisfied 9 (12%) 13 (17.3%)
Moderately dissatisfied 8 (10.7%) 14 (18.6%)
Very dissatisfied 8 (10.7%) 13 (17.3%)
GAQ
GAQ1, Yes, n (%) 65 (86.7%) 57 (76%) 0.093
GAQ2, Yes, n (%) 53 (70.7%) 46 (61.3%) 0.22
Sexual bother (UCLA-PCI) 37.14 ± 21.45 37.54 ± 19.67 0.759
Report of nocturnal erection (UCLA-PCI) 0.002
Never 60 (80.5%) 49 (64.9%)
Less than 25% 7 (9.8%) 24 (31.6%)
Less than 50% 4 (4.9%) 0 (0%)
More than 50% 4 (4.9%) 1 (1.8%)
More than 75% 0 (0%) 1 (1.8%)
Results are means (±standard deviation). Significant values are in bold
IIEF = International Index of Erectile Function; IIEF domains: EF = erectile function; OF = orgasmic function; SD = sexual drive; IS = intercourse satisfaction;
OS = overall satisfaction; EHS = erection hardness score; IAI = intracavernous alprostadil injection
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No case of priapism or penile curvature was
noted in the population studied.
Discussion
SR following RP consists of the use of a drug
or device to maximize recovery of functional
erections. Although speciﬁc SR programs for
postprostatectomy erectile dysfunction have been
developed, the best therapeutic regime remains
undetermined, and the effectiveness in restoring
the preoperative level of erectile function is difﬁcult
to judge [9]. The concept of early postoperative
vasoactive therapy with IAI was ﬁrst introduced in
1997 [6]. As IAI treatment may be painful and
troublesome, concern is often expressed by patients
as to how long this treatment should be continued
before reaching the maximal effect concerning
erectile function. Unfortunately, the rate of recov-
ery of erectile function in patients that have already
used IAI for 1 year is poorly documented [24,25].
In the present study, we found that the response
to IAI treatment and the number of injection per-
formed per week by the patient remained stable
between 1 and 2 years following RP. The overall
rate of nocturnal erections improved and the
majority of patients responded afﬁrmatively to
GAQ 1 (“Has the treatment you have been taking
improved your erectile function?”) and GAC Q2
(“If yes, has the treatment improved your ability to
engage in sexual activity?”) at M12 and M24 dem-
onstrating a subjective beneﬁcial effect of IAI.
However, the return of spontaneous erectile func-
tion during intercourse attemptswas not signiﬁcant
for most patients, and the treatment satisfaction
was signiﬁcantly lower at M24 suggesting some
lassitude toward continuing injections. Impor-
tantly, spontaneous erectile function decreased in
30.6% of patients at M24 in comparison to M12, a
fact that has never been reported in patients using
IAI. Only 33 patients (44%) reported improved EF
scores, but no cases of normalization of erectile
function (IIEF-EF without treatment >24) were
reported, and no patient considered that they had
recovered their preoperative level. Only four
patients had an EHS score >2 without treatment at
M24, indicating that spontaneous erection after 2
years of IAI use, if present, was not rigid enough to
achieve sexual penetration. Interestingly, at the
M24 follow-up, 28 patients (37.3%) patients were
using PDE5i or a vacuum in association with IAI.
This suggests that patients had sought additional
therapy to IAI in order to further improve their
sexual function, even thoughPDE5i had previously
been ineffective at 1 year.
Signiﬁcant correlations were found between
IIEF scores of patients receiving treatment at M12
and at M24. However, better responses to IAI at
M12, as identiﬁed by using the IIEF-EF and EHS
scores, were not associated with greater recovery
of natural erectile function at M24. Higher SD
present at M12 was the only factor associated with
an improved IIEF-EF score without treatment at
M24. This raises important questions concerning
the concept of penile rehabilitation, since intui-
tively, one could have assumed that the higher the
erectile function and penile rigidity obtained with
IAI, the better the chances of recovering natural
erection functions.
A possible explanation for the lack of erectile
function recovery could be the low mean IIEF
subscores with IAI. These were inferior to those
reported in other settings [24–26]. In a study of
patients treated with IAI after non-nerve-sparing
RP, Titta et al. [24] reported an IIEF-EF subscore
of 26.5 after 18 months postsurgery, compared
with a score of 18.07 after 24 months in our study.
All patients included in their study were alprostadil
Table 3 Correlations between IIEF scores and satisfaction with IAI use reported at M12; IIEF and EHS scores at M24;
and improvement of spontaneous erections between M12 and M24 (Δ IIEF-EF without IAI)
M12 IIEF-SD M12 IIEF-IS M12 IIEF-EF (IAI) M12 IIEF-EHS (IAI) M12 SATISF IAI
Rho P value Rho P value Rho P value Rho P value Rho P value
M24 EHS without IAI −0.008 0.945 0.045 0.708 0.074 0.533 0.146 0.228 0.032 0.789
M24 EHS with IAI 0.267 0.025 0.273 0.021 0.368 0.002 0.294 0.015 0.235 0.052
M24 IIEF-EF without IAI 0.227 0.050 0.161 0.167 0.159 0.173 0.160 0.179 −0.069 0.566
M24 IIEF-EF with IAI 0.287 0.012 0.427 0.000 0.438 <0.0001 0.184 0.122 0.278 0.018
Δ IIEF-EF without IAI 0.277 0.016 0.204 0.080 0.073 0.533 0.061 0.614 −0.195 0.101
M24 IIEF-OF 0.332 0.004 0.422 0.000 0.485 <0.0001 0.274 0.021 0.307 0.009
M24 IIEF-IS 0.328 0.004 0.510 <0.0001 0.461 <0.0001 0.224 0.058 0.313 0.007
M24 IIEF-SD 0.418 0.000 0.299 0.009 0.249 0.031 0.134 0.263 0.167 0.161
Significant values are in bold
IIEF = International Index of Erectile Function; IIEF domains: EF = erectile function; OF = orgasmic function; SD = sexual drive; IS = intercourse satisfaction;
EHS = erection hardness score; IAI = intracavernous alprostadil injection
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responsive at the beginning of the study, whereas
in our study, this was not an inclusion criterion.
Some of our patients were poor responders to IAI
but agreed to continue with the treatment with the
purpose of SR. This could explain why the
IIEF-EF subscores were different at a longer
follow-up period. Further studies with a greater
number of patients are required to conﬁrm this
hypothesis and to investigate the role of other
factors that may inﬂuence the recovery of sponta-
neous erection in IAI users.
One of the chief questions investigated in our
study was to determine how long the SR process
should be prolonged in order to reach the maximal
effect. Recovery of normal erection function has
previously been reported up to 4 years following
RP [27], with 19.8% of patients experiencing
marked or moderate improvement in erectile
function between 24 and 48 months after surgery.
In the study, patients using IAI were excluded from
analysis, and potency was deﬁned as the ability to
engage in sexual intercourse at least once per
month with or without the use of PDE5i. Our
study design differs radically as we included
patients who did not respond to PDE5i at M12
and for whom IAI was considered the main thera-
peutic option to achieve sexual intercourse. Our
results indicate that in such patients, the rate of
recovery of erectile function may be much lower
than other populations studied. The fact that
30.6% of patients in our study reported a wors-
ened erection after 2 years of IAI use should be
taken into consideration during patient counsel-
ing, particularly if use of IAIs is perceived as
troublesome and can cause pain. It is unlikely that
patients with an impairment of their natural erec-
tile function after 2 years of IAI use would subse-
quently beneﬁt from the same treatment regime.
Due to the overall low rate of recovery of sponta-
neous erection at M24, it is suggested that patients
who are dissatisﬁed with IAI after 1 year of use
should be offered another therapeutic option, such
as a penile implant or combination of other
erectogenic drugs or devices.
Finally, the beneﬁcial effects of IAI should be
compared with those of other therapies, in particu-
lar the use of PDE5i. At present, there are no
comparative studies to demonstrate a better
outcome with any of the available pharmacological
treatments. As a consequence, there is a lack of
recommendations concerning the best regimen to
use for SR [9]. Recently Mulhall et al. [9] con-
cluded that they were unable to determine the
optimal approach to SR and to deﬁne “what rep-
resents the optimal rehabilitation program in
regard to strategies utilized, timing of interven-
tion, or duration of treatment” [28].
During the time period of the study, we did not
offer PDE5i treatment to patients during the ﬁrst
year following RP—except if the patient reported
spontaneous erections—as our experience and
others suggest that PDE5i is not efﬁcient before
the ninth month following surgery [5]. Since
numerous studies have demonstrated that early
PDE5i therapy is beneﬁcial for SR and penile oxy-
genation following RP [2,9,10], we now propose
that PDE5i is offered systematically 1 month after
RP in combination with IAI or a vacuum and that
patients may choose the best regime according to
their preference and suitability, with the aim of
achieving satisfactory intercourse and SR.
However, in our population of patients, a signiﬁ-
cant number of patients discontinued use of
PDE5i due to the costs involved and the lack of
efﬁcacy which has also been mirrored in other
studies [28,29].
Consequently, IAI still represents one of the
main therapeutic options for SR following RP, and
we consider that the long-term outcomes of this
treatment deserve particular attention. Overall,
our study emphasizes that longer follow-up of
patients with speciﬁc evaluation tools should be
proposed in all IAI users in order to adapt the
treatment and counsel patients as to other thera-
peutic options when results are unsatisfactory.
Conclusion
The improvement of natural erectile function after
the ﬁrst year of using IAI is limited, and impair-
ment of natural erectile function may occur in
some patients with pRPED. This suggests that
patients using IAI who do not respond well to
PDE5i within 1 year following surgery should be
encouraged to continue with IAI only if it enables
the patient to engage in satisfying intercourses.
Patients should be informed of the limitations of
using IAI and the limited effect on natural erec-
tions. Patients dissatisﬁed with IAI after 1 year
should be offered another therapeutic option.
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